MX2023009313A - Terapia conjunta para el tratamiento de trastornos convulsivos. - Google Patents

Terapia conjunta para el tratamiento de trastornos convulsivos.

Info

Publication number
MX2023009313A
MX2023009313A MX2023009313A MX2023009313A MX2023009313A MX 2023009313 A MX2023009313 A MX 2023009313A MX 2023009313 A MX2023009313 A MX 2023009313A MX 2023009313 A MX2023009313 A MX 2023009313A MX 2023009313 A MX2023009313 A MX 2023009313A
Authority
MX
Mexico
Prior art keywords
seizure disorders
methods
treating seizure
conjoint therapy
human
Prior art date
Application number
MX2023009313A
Other languages
English (en)
Inventor
Jr James Philip Johnson
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of MX2023009313A publication Critical patent/MX2023009313A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En determinadas modalidades, la presente divulgación se refiere a métodos y usos para tratar trastornos convulsivos en un ser humano que lo necesite, en los que los métodos y usos comprenden la administración conjunta de N-[4-(6-fluoro-3,4-dihidro-1H-isoqui nolin-2-il)-2,6-dimetilfenil]-3,3-dimetilbutanamida (Compuesto A) y un medicamento anticonvulsivo (ASM) al ser humano en cantidades que son efectivas terapéuticamente cuando se administran conjuntamente. La presente divulgación se dirige además a varios métodos mejorados de terapia y administración del Compuesto A.
MX2023009313A 2021-02-09 2022-02-09 Terapia conjunta para el tratamiento de trastornos convulsivos. MX2023009313A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163147736P 2021-02-09 2021-02-09
PCT/US2022/015851 WO2022173853A1 (en) 2021-02-09 2022-02-09 Conjoint therapy for treating seizure disorders

Publications (1)

Publication Number Publication Date
MX2023009313A true MX2023009313A (es) 2023-08-16

Family

ID=80682617

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023009313A MX2023009313A (es) 2021-02-09 2022-02-09 Terapia conjunta para el tratamiento de trastornos convulsivos.

Country Status (14)

Country Link
US (1) US20220288057A1 (es)
EP (1) EP4291185A1 (es)
JP (1) JP2024506584A (es)
KR (1) KR20240004238A (es)
CN (1) CN117015379A (es)
AU (1) AU2022218962A1 (es)
CA (1) CA3207002A1 (es)
CL (1) CL2023002323A1 (es)
CO (1) CO2023011948A2 (es)
IL (1) IL304918A (es)
MA (1) MA61730A1 (es)
MX (1) MX2023009313A (es)
TW (1) TW202245743A (es)
WO (1) WO2022173853A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8993593B2 (en) 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
NZ575652A (en) 2006-08-23 2011-08-26 Valeant Pharmaceuticals Int Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
MD3790548T2 (ro) * 2018-05-11 2024-02-29 Xenon Pharmaceuticals Inc Metode de îmbunătățire a biodisponibilității și expunerii activatorului de canale de potasiu voltaj-dependente
WO2021092439A1 (en) * 2019-11-08 2021-05-14 Xenon Pharmaceuticals Inc. Methods of treating depressive disorders
CN116847843A (zh) * 2021-02-09 2023-10-03 泽农医药公司 用于治疗快感缺乏的电压门控的钾通道开放剂

Also Published As

Publication number Publication date
WO2022173853A1 (en) 2022-08-18
CA3207002A1 (en) 2022-08-18
CO2023011948A2 (es) 2023-11-20
TW202245743A (zh) 2022-12-01
MA61730A1 (fr) 2024-01-31
AU2022218962A1 (en) 2023-09-14
JP2024506584A (ja) 2024-02-14
US20220288057A1 (en) 2022-09-15
CL2023002323A1 (es) 2024-03-08
EP4291185A1 (en) 2023-12-20
KR20240004238A (ko) 2024-01-11
IL304918A (en) 2023-10-01
CN117015379A (zh) 2023-11-07

Similar Documents

Publication Publication Date Title
MX2020012008A (es) Métodos para potenciar la biodisponibilidad y la exposición de un abridor de canales de potasio dependientes de voltaje.
MX2021014158A (es) Uso de cannabidiol en el tratamiento de espasmos epilepticos.
US20190314441A1 (en) Method For The Management Of Cancer And Cancer Treatment-Related Comorbidities
Yang et al. Galangin inhibits LPS-induced MMP-9 expression via suppressing protein kinase-dependent AP-1 and FoxO1 activation in rat brain astrocytes
MX2022005490A (es) Metodos para el tratamiento de trastornos depresivos.
WO2023088497A3 (zh) 一种氧化氮供体型贝前列素类衍生物及其药物组合物和用途
MX2023009313A (es) Terapia conjunta para el tratamiento de trastornos convulsivos.
CN105311081A (zh) 山海丹野菊花注射液在雾化吸入、喷瓶气雾、直肠给药的应用及方法
CN111789809A (zh) 大麻提取物透皮装置及其制备方法
MX2022006877A (es) Uso de un abridor de canal de potasio kv7 para tratar el dolor.
US7470666B2 (en) Use of Ulinastatin and its pharmaceutical composition for treating severe acute respiratory syndrome
WO2022110568A1 (zh) 维生素c和双硫仑在制备抗肿瘤联合用药物中的用途
MX2023007150A (es) Compuestos de pirazol que contienen boro, composiciones que los comprenden, métodos y usos de los mismos.
CN112353877A (zh) 缬草总生物碱提取物在制备马拉色菌抑制剂中的用途
US6916845B2 (en) Method for prevention and treatment of male and female sexual dysfunction
Stone et al. The prophylaxis and treatment of postpartum and postoperative ileus with pantothenyl alcohol
CN111603458B (zh) 一种用于治疗卵巢癌的组合物
WO2014142705A1 (ru) Цитокинсодержащее лекарственное средство, обладающее противовирусным, противомикробным, иммуномодулирующим и противовоспалительным действием для лечения и профилактики инфекционных заболеваний
CN108853246B (zh) 一种消炎镇痛中药组合物及其制备方法和应用
Sandhya et al. Evaluation of two antiemetic agents during outpatient gynaecological surgery
JP2006008540A (ja) 風邪薬
OTHERAPY Clark, MD, No. 66 W. Tenth Street, of New York, plainly outlines the useful combination of two leading remedies
GB2619486A (en) Compositions and methods for improving brain function
RU2179468C2 (ru) Способ проведения наркоза
UA125849U (uk) Спосіб лікування післяпологових рубців